Valstar M H, de Ridder M, van den Broek E C, Stuiver M M, van Dijk B A C, van Velthuysen M L F, Balm A J M, Smeele L E
Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Oral and Maxillofacial Surgery, Academic Medical Centre, University of Amsterdam, The Netherlands.
Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Radiotherapy, Academic Medical Centre, University of Amsterdam, The Netherlands.
Oral Oncol. 2017 Mar;66:93-99. doi: 10.1016/j.oraloncology.2017.01.004. Epub 2017 Jan 23.
Whereas salivary gland pleomorphic adenoma (SGPA) is the most common type of salivary gland tumor, little is known about its epidemiology because national cancer registries do not register this disease.
To establish SGPA incidence trends, rates of secondary malignant transformation and recurrence and associated factors in the Netherlands.
Data on incidence, epidemiology, secondary malignant transformation and recurrence were retrieved from the Dutch pathology registry (PALGA) for the years 1992, 1997, 2002, 2007, and 2012. Multivariate analysis was performed to discover the risk factors for recurrence.
3506 cases of SGPA were recorded implying an overall European standardized rate of 4.2-4.9 per 100,000 person-years. Our figures showed a female preponderance (1:1.43) with an annual 1% rise in female incidence (95% confidence interval [CI]: 0.2-1.8) and a bimodal age distribution in women (p<0.0001). The overall 20-year recurrence rate was 6.7%, and median time to first recurrence was 7years. Positive and uncertain resection margins and younger age at diagnosis were risk factors for recurrence, with odds ratios (ORs) of 4.62 (95%CI 2.84-7.51), 4.08 (95%CI 2.24-7.43), and 0.42 (95%CI 0.29-0.63) respectively. Tumor locations in the minor salivary glands had lower odds of recurrence than tumors in the parotid (OR 0.24; 95% CI: 0.07-0.77; p<0.016). Malignant transformation occurred in 0.15% of SGPAs (3.2% of recurrences).
This first nationwide study clearly showed sex differences in SGPA epidemiology, possibly suggesting some underlying hormonal mechanism. Long-term recurrence risks were low, and secondary malignant transformation risks were very low.
涎腺多形性腺瘤(SGPA)是涎腺肿瘤最常见的类型,但由于国家癌症登记处未登记该疾病,其流行病学情况鲜为人知。
确定荷兰SGPA的发病趋势、继发性恶性转化和复发率及相关因素。
从荷兰病理登记处(PALGA)检索1992年、1997年、2002年、2007年和2012年的发病率、流行病学、继发性恶性转化和复发数据。进行多变量分析以发现复发的危险因素。
记录了3506例SGPA病例,意味着欧洲总体标准化发病率为每10万人年4.2 - 4.9例。我们的数据显示女性占优势(1:1.43),女性发病率每年上升1%(95%置信区间[CI]:0.2 - 1.8),且女性年龄分布呈双峰型(p<0.0001)。总体20年复发率为6.7%,首次复发的中位时间为7年。手术切缘阳性和不确定以及诊断时年龄较小是复发的危险因素,比值比(OR)分别为4.62(95%CI 2.84 - 7.51)、4.08(95%CI 2.24 - 7.43)和0.42(95%CI 0.29 - 0.63)。小涎腺肿瘤的复发几率低于腮腺肿瘤(OR 0.24;95%CI:0.07 - 0.77;p<0.016)。0.15%的SGPA发生了恶性转化(复发的3.2%)。
这项首次全国性研究清楚地显示了SGPA流行病学中的性别差异,可能暗示了一些潜在的激素机制。长期复发风险较低,继发性恶性转化风险非常低。